- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
| Mi | China's CARsgen Slides for Second Day on Hefty Price Tag for World's First Solid Tumor CAR-T Therapy | 3 | Yicai Global | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.06. | CARsgen makes history as China approves world's first CAR-T therapy for solid tumors | 1 | FiercePharma | ||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | 2 | pharmaphorum | ||
| 22.06. | CARsgen's Solid-Tumor CAR-T Therapy Nears China Approval, a Global First | 1 | Yicai Global | ||
| 22.06. | CARSGEN-B (02171): INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE NEW DRUG APPLICATION FOR THE CLAUDIN18.2 CAR T-CELL THERAPY PRODUCT SATRICABTAGENE ... | 1 | HKEx | ||
| 15.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AND CT1190B AT 2026 EHA ANNUAL CONGRESS | 1 | HKEx | ||
| 01.06. | CARsgen Therapeutics: Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting | 73 | PR Newswire | SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 01.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON SATRI-CEL AT THE 2026 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 26.05. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | CARSGEN-B (02171): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 4 | HKEx | ||
| 22.05. | CARSGEN-B (02171): NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 5 | HKEx | ||
| 22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026 | - | HKEx | ||
| 22.05. | CARSGEN-B (02171): CLARIFICATION ANNOUNCEMENT | 1 | HKEx | ||
| 15.05. | CARSGEN-B (02171): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 27.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,08 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,93 | +6,75 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | +3,43 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | Qiagen und das KI-Thema | Die Analysten der DZ Bank sehen bei Qiagen viele aussichtsreiche Wachstumstreiber. Mittelfristig zeigen sich dadurch gute Perspektiven. Beim Thema KI profitiert Qiagen auf mehreren Ebenen, sei es bei... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | +1,58 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +1,21 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | +14,24 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | +1,68 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | -0,37 % | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? | ||
| MINERALYS THERAPEUTICS | 26,880 | +0,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | +5,42 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | +4,18 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | +2,14 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | +6,36 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | +0,40 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.